The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

The news will intensify pressure on Pfizer Chief Executive Officer Albert Bourla, who has repeatedly pointed to the drugmaker ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.